C4 Therapeutics (CCCC) Capital Expenditures (QoQ) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 499.92 Mn | 246.25 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.19% |
| Mar 31, 2026 | 481.82% |
| Dec 31, 2025 | -96.36% |
| Sep 30, 2025 | 2.72% |
| Dec 31, 2024 | 69.23% |
| Sep 30, 2024 | -106.60% |
| Dec 31, 2023 | -73.83% |
| Sep 30, 2023 | 65.75% |
| Jun 30, 2023 | -38.54% |
| Mar 31, 2023 | -60.47% |
| Dec 31, 2022 | 102.45% |
| Sep 30, 2022 | -76.24% |
| Jun 30, 2022 | 1,701.16% |
| Mar 31, 2022 | 57.80% |
| Jun 30, 2021 | -38.23% |
| Mar 31, 2021 | 148.11% |
| Dec 31, 2020 | 2.46% |
| Sep 30, 2020 | 360.55% |
| Jun 30, 2020 | -159.24% |
| Mar 31, 2020 | 352.05% |